(C) 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“Background: The long-term antiproteinuric effects of benidipine, a calcium channel blocker (CCB), have not been evaluated
in detail in hypertensive patients with chronic kidney disease (CKD).
Methods: Benidipine (4 mg/day) was administered to previously untreated hypertensive patients with CKD, or hypertensive patients with CKD not achieving target blood pressure (BP) despite taking buy Erastin an angiotensin II receptor blocker (ARB). The patients were followed up for 1 year. If target BP was not achieved by 2 weeks after the start of benidipine treatment, the dosage was increased to 8 mg/day. The urinary protein to creatinine (UP/cre) ratio was evaluated before and after benidipine treatment.
Results: This study evaluated 65 hypertensive patients with CKD. BP (systolic/diastolic) decreased from 154 +/- 19 / 91 +/- 12 mm Hg before treatment to 134 +/- 16 / 78 +/- 10 mm Hg
at 1 year after treatment (p<0.001). The UP/cre ratio decreased significantly from 2.21 +/- 2.47 g/g creatinine (g/g cre) before treatment to 1.43 +/- 2.21 g/g cre after treatment (p<0.001). PD98059 manufacturer In both the untreated and ARB-treated groups, the BP and UP/cre ratio decreased significantly at 1 year after treatment. The percentage change in the UP/cre ratio was signifi-cantly greater in patients aged 65 years or older than in those less than 65 years (79.1% vs. 48.7%, p=0.038).
Conclusions: Benidipine treatment reduced the UP/cre ratio in hypertensive patients with CKD, and the percentage decrease of the UP/cre ratio was greater in elderly patients, suggesting that benidipine may have more potent antiproteinuric effects in elderly hypertensive patients with CKD.”
“Objectives: Examine the effectiveness of an advanced pneumatic compression device (APCD) in reducing limb-volume (LV), and to evaluate clinician and patient-reported outcomes.
Design: Device registry study.
Materials and methods: Data were collected prospectively for 196 lower extremity lymphedema patients prescribed an APCD. Baseline and post-treatment
LVs were calculated and clinical outcomes (skin changes, pain, and function) were assessed. Patient-reported outcomes and satisfaction Fedratinib utilizing a pre- and post-treatment survey were also evaluated.
Results: 90% of APCD-treated patients experienced a significant reduction in LV with 35% enjoying a reduction >10%. Mean LV reduction was 1,150 mL or 8% (p<.0001). Greater baseline LV and BMI were strong predictors of LV reduction (p<.0001). Clinician assessment indicated that the majority of patients experienced improvement in skin fibrosis and function. Patient-reported outcomes showed a significant increase in ability to control lymphedema through APCD treatment, with an increase in function and a reduction in the interference of pain.